### Vancomycin

**Indication:** Endophthalmitis  
**ICD11 code:** 9C21

- **INN:** Vancomycin  
- **Medicine type:** Chemical agent  
- **Antibiotic groups:** WATCH

- **List type:** Core

- **Formulations:** Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection

- **EML status history:**  
  - First added in 2021 (TRS 1035)  
  - Changed in 2023 (TRS 1049)

- **Sex:** All

- **Age:** Also recommended for children

- **Therapeutic alternatives:** The recommendation is for this specific medicine

- **Patent information:** Patents have expired in most jurisdictions  
  Read more about patents.

- **Wikipedia:** [Vancomycin](https://en.wikipedia.org/wiki/Vancomycin)

- **DrugBank:** [Vancomycin](https://www.drugbank.ca/drugs/DB00004)

---

**Expert Committee recommendation**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:  
- the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.  
- the addition of new strength formulations of IV vancomycin (500 mg, 1 g (as hydrochloride) on the EMLc.

**EML recommendations: Endophthalmitis**

<table>
<thead>
<tr>
<th>First choice</th>
<th>Second choice</th>
</tr>
</thead>
<tbody>
<tr>
<td>cephalosporins</td>
<td>cephalosporins</td>
</tr>
<tr>
<td>co-prescribed with <a href="https://www.drugbank.ca/drugs/DB00004">vancomycin</a></td>
<td>co-prescribed with <a href="https://www.drugbank.ca/drugs/DB00004">vancomycin</a></td>
</tr>
<tr>
<td>ceftriaxone</td>
<td>ceftriaxone</td>
</tr>
</tbody>
</table>